Home > Insider Trading > Filing (0001209191-19-010303)

Filing Details

Accession Number:: 0001209191-19-010303
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-14 17:28:50
Reporting Period:: 2019-02-12

Accepted Time:: 2019-02-14 17:28:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-12	3,050,329	$0.00	3,372,392	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-02-12	3,157,506	$0.00	6,529,898	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-02-12	835,705	$0.00	7,365,603	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-02-12	559,215	$0.05	7,924,818	No	4	X	Indirect	See Footnote
Common Stock	Disposition	2019-02-12	1,971	$14.00	7,922,847	No	4	S	Indirect	See Footnote
Common Stock	Acquisiton	2019-02-12	500,000	$14.00	8,422,847	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	X	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-02-12	3,050,329	$0.00	3,050,329	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-12	3,157,506	$0.00	3,157,506	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-02-12	835,705	$0.00	835,705	$0.00
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	25,418	$0.00	25,418	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	57,192	$0.00	57,192	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	171,579	$0.00	171,579	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	50,837	$0.00	50,837	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	152,514	$0.00	152,514	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	101,675	$0.00	101,675	$0.05

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
		No	4	C	Indirect
		No	4	C	Indirect
		No	4	C	Indirect
2015-03-23	2025-03-24	No	4	X	Indirect
2015-07-23	2025-07-23	No	4	X	Indirect
2015-08-19	2025-08-19	No	4	X	Indirect
2015-12-16	2025-12-16	No	4	X	Indirect
2016-11-01	2026-11-01	No	4	X	Indirect
2017-01-10	2027-01-10	No	4	X	Indirect

Footnotes

All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer'sinitial public offering and have no expiration date.
The shares are held as follows: 1,382,777 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,229 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,158 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,525,165 by UBS Oncology Impact Fund L.P. ("UBS Oncology") and 322,063 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Ansbert Gadicke is a member of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC) is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Director of Oncology GP LLC and a member of AM LLC.
The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares are held as follows: 2,814,142 by BV 2014, 187,696 by BV 2014(B), 102,077 AM BV2014, 3,103,920 by UBS Oncology and 322,063 by AM LLC.
The shares are held as follows: 3,192,985 by BV 2014, 212,964 by BV 2014(B), 115,818 AM BV2014, 3,521,773 by UBS Oncology and 322,063 by AM LLC.
On February 12, 2019, BV 2014, BV 2014(B), AM BV2014 and UBS Oncology exercised warrants to purchase an aggregate of 559,215 shares of the Issuer's common stock for $0.0492 per share. The warrants were exercised as follows: 391,784 by BV 2014, 26,129 by BV 2014(B), 14,206 by AM BV2014 and 127,096 by UBS Oncology. The exercise price was paid on a cashless basis, resulting in the Issuer's withholding of an aggregate of 1,971 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 557,244shares.
The shares are held as follows: 3,584,769 by BV 2014, 239,093 by BV 2014(B), 130,024 AM BV2014, 3,648,869 by UBS Oncology and 322,063 by AM LLC.
The shares are held as follows: 3,583,391 by BV 2014, 238,998 by BV 2014(B), 129,973 AM BV2014, 3,648,422 by UBS Oncology and 322,063 by AM LLC.
The shares are held as follows: 3,810,051 by BV 2014, 254,116 by BV 2014(B), 138,195 AM BV2014, 3,898,422 by UBS Oncology and 322,063 AM LLC.
No securities held by the Reporting Person.